Related Experiment Video
Updated: Jan 30, 2026
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
Published on: June 5, 2020
Protease inhibitors for the treatment of hepatitis C virus infection
Philipp de Leuw1, Christoph Stephan1
1Goethe-University Hospital Frankfurt, Medical Clinic II, Infectious Diseases Unit, Frankfurt am Main, Germany.
Insights
Direct-acting antivirals (DAAs) offer effective and safe hepatitis C virus (HCV) treatment, surpassing older therapies. Third-generation NS3/4A protease inhibitors achieve high cure rates, even in difficult-to-treat populations.
Area of Science:
- Hepatology and Virology
- Infectious Diseases
- Pharmacology
Background:
- Hepatitis C virus (HCV) affects 80 million globally, posing a significant public health challenge.
- HCV/HIV coinfection is prevalent (25-30% in Europe/US), complicating treatment.
- Previous HCV treatments (pegylated interferon/ribavirin with NS3/4A inhibitors) had high side effect rates.
Purpose of the Study:
- To review current literature and clinical evidence on NS3/4A protease inhibitors for HCV treatment.
- To discuss the impact of direct-acting antivirals (DAAs) on HCV eradication.
- To address treatment challenges in HIV- and HBV-coinfected patients.
Main Methods:
- Literature review of current scientific publications and clinical trial data.
- Analysis of treatment efficacy, safety, and tolerability of DAAs.
- Focus on third-generation pan-genotypic NS3/4A protease inhibitors.
Main Results:
- Oral DAAs provide excellent efficacy, safety, and tolerability for HCV treatment.
- Third-generation NS3/4A protease inhibitors (grazoprevir, glecaprevir, voxilaprevir) demonstrate high antiviral activity.
- Combination therapy with NS5A inhibitors achieves >95% cure rates, irrespective of baseline resistance-associated variants (RASs).
Conclusions:
- Modern DAAs, particularly third-generation NS3/4A protease inhibitors, represent a significant advancement in HCV therapy.
- These DAAs offer a highly effective option for eradicating HCV, including in difficult-to-treat patient groups.
- Further research is needed to optimize treatment strategies for coinfected individuals.
Abstract:
The hepatitis C virus (HCV) has affected an estimate of 80 million individuals worldwide and is a strain of public health. Around 25-30% of patients in Europe and the US infected with HIV are coinfected with HCV. Despite treatment modalities containing a NS3/4A protease inhibitor in combination with pegylated interferon and ribavirin prior to 2013 improved SVR rates, the amount of severe side effects was high. Nowadays, oral direct-acting antivirals (DAAs) combination therapy offers excellent treatment efficacy, safety and tolerability. This review focuses on current literature and clinical evidence and their impact regarding NS3/4A protease inhibitors. In addition, pitfalls in treatment from HIV- and HBV-coinfected patients will also be discussed. In the era of DAA treatment, the third-generation pan-genotypic NS3/4A protease inhibitors (mainly grazoprevir, glecaprevir and voxilaprevir) show a high antiviral activity and genetic resistance barrier with cure rates of over 95% when combined with an NS5A inhibitor, irrespectively of baseline resistance associated variants (RASs) being present. These new key components of DAA combination therapy are impressive options to eradicate HCV in the so called difficult-to-treat population (e.g. compensated cirrhosis, end-stage renal disease and patients who failed previous DAA treatment).
More Related Videos
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
00:50What are Viruses?
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:21Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...